Leiden, the Netherlands, 28 February 2013. Â Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced that at its
Extraordinary General Meeting (EGM) of shareholders, held today, all proposals
were approved, including an amendment of its articles of association effecting a
10:1 reverse share split and a reduction of the nominal value of the combined
shares.
Pursuant to the reverse share split, every ten shares of Pharming with a nominal
value of EUR 0.01 each will be combined into one share with a nominal value of
EUR 0.10 each, and the nominal value of these new shares will be reduced to EUR
0.01 each.
Trading in the new shares with ISIN Code NL0010391025 will start on Tuesday 5
March 2013. No actions from shareholders are required.
Following the reverse share split, Pharming will have approximately 118.9
million shares outstanding with a nominal value of EUR 0.01 each.
Any shareholders that have specific questions on the reverse share split should
contact their account bank.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. RUCONEST(®) is a recombinant human C1 inhibitor approved for the
treatment of angioedema attacks in patients with HAE in all 27 EU countries plus
Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish
Orphan Biovitrum. RUCONEST(®) is partnered with Santarus Inc (NASDAQ: SNTS) in
North America where the drug has completed Phase III clinical development. The
product is also being evaluated for various follow-on indications. Pharming has
a unique GMP compliant, validated rabbit platform for the production of
recombinant human proteins that, with the EU approval of Pharming's rhC1
inhibitor, has proven capable of producing industrial volumes of high quality
recombinant human protein in a significantly more economical way through low
upfront capital investment and manufacturing costs, compared to current cell
based technologies. Pharming now plans to utilise this platform for the
development of rhFVIII for the treatment of Haemophilia A.
Additional information is available on the Pharming website, www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact
Sijmen de Vries, CEO: T: +31 524 7400
# # #
Press release (PDF):
http://hugin.info/132866/R/1682112/550148.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1682112]
